Diacylglycerol acyltransferase 2 inhibitors
AssigneePfizer Inc.
InventorKentaro Futatsugi
Life of this patent
Estimating the term…
Abstract
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Claims4
A method for treating non-alcoholic steatohepatitis (NASH) in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound having the structure:
- or a pharmaceutically acceptable salt thereof.
A method for treating non-alcoholic steatohepatitis (NASH) in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound comprising 3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid or (R)-3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.